5 Buy-Rated Stocks with Latest Insider Purchases
Robert James Wills, a director at Oncternal Therapeutics Inc (NASDAQ:ONCT), bought 3,086 shares of Oncternal Therapeutics Inc (NASDAQ:ONCT) at $8.96 per share.
Oncternal Therapeutics Inc. (ONCT)
Market is closed
News
- Displaying 8
10 Underperforming Stocks Insiders are Buying
In this article, we will take a detailed look at the 10 Underperforming Stocks Insiders are Buying. For a quick overview of such stocks, read our article 5 Underperforming Stocks Insiders are Buying...
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript
Operator: Greetings, and welcome to Oncternal's Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q2 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Oncternal Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Oncternal Therapeutics First Quarter 2023 Financial Results Call. As a reminder, this conference will be recorded.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript
Operator: Greetings and welcome to the Oncternal Therapeutics, Inc. Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Is Oncternal Therapeutics (ONCT) A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Billionaire Hedge Funds
